TriangleDISEASE & TREATMENT SETTING
Non-Small Cell Adenocarcinoma
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Non-Small Cell Adenocarcinoma
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 1 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
- source wording
- Source null
Study evidence for this setting
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
CAR T Cells in Mesothelin Expressing Cancers
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Milademetan in Advanced/Metastatic Solid Tumors
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-non-small-cell-adenocarcinoma
- binding id
- ncit-C27745
- source collection
- ncit-concept
- source key
- C27745
- source excerpt
- Source null
- match status
- exact
- match note
- Source null
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice